What is Rectify Pharmaceuticals?
Rectify Pharmaceuticals, based in Cambridge, MA, is a biotechnology firm dedicated to developing Positive Functional Modulators (PFMs). These disease-modifying precision therapeutics are engineered to restore ABC transporter function, offering new hope for patients afflicted with serious genetic diseases. The company's focus on precision medicine and genetic disorders positions it at the forefront of therapeutic innovation.
How much funding has Rectify Pharmaceuticals raised?
Rectify Pharmaceuticals has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2021): $100M with participation from Omega Fund Management, Atlas Venture, and Forbion
Key Investors in Rectify Pharmaceuticals
Omega Fund Management
Omega Fund Management is a venture capital firm focused on investing in exceptional founders and impactful products across various therapeutic areas, including oncology, immunology, and precision medicine, aiming to bring science to patients.
Atlas Venture
Atlas Venture is an early-stage venture capital firm dedicated to creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines, partnering with entrepreneurs to support innovative biotech startups.
Forbion
Forbion is a global life sciences venture capital firm that sources, builds, and guides biotech and biopharmaceutical companies from early stage through clinical development, with a focus on innovative therapeutics in Europe and North America.
What's next for Rectify Pharmaceuticals?
The substantial enterprise-level funding Rectify Pharmaceuticals has garnered indicates a strong market confidence in its PFM technology and its potential to address unmet needs in genetic disease treatment. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling further clinical trials and the scaling of its therapeutic solutions. The strategic nature of the recent investment suggests a collaborative approach with key partners to advance its mission of restoring ABC transporter function and bringing life-changing therapies to patients.
See full Rectify Pharmaceuticals company page
